Gastric Cancer – Epidemiology – Epidemiology – Gastric Cancer – Mature Markets

Clarivate Epidemiology’s coverage of gastric cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of gastric cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s gastric cancer forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with gastric cancer each year?
• How will improvements in survival change the number of first-line drug-treatment opportunities for gastric adenocarcinoma?
• How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for gastric adenocarcinoma?
• Of all people diagnosed with gastric adenocarcinoma, how many in each of the major pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of gastric adenocarcinoma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology provides at least 10 years of forecast data for the following gastric cancer patient populations:

• Diagnosed incident cases of gastric cancer.
• Diagnosed adenocarcinoma incident cases.
• Diagnosed adenocarcinoma incident cases by site (cardia vs. non-cardia).
• Diagnosed adenocarcinoma incident cases by HER2 status.
• Diagnosed adenocarcinoma incident cases by stage at diagnosis.
• Diagnosed adenocarcinoma prevalent cases.
• Diagnosed first-line unresectable/metastatic HER2-positive drug-treatable population.
• Diagnosed first-line unresectable/metastatic HER2-negative drug-treatable population.
• Diagnosed second-, third- and fourth-line unresectable/metastatic HER2-positive drug-treatable population.
• Diagnosed second-, third- and fourth-line unresectable/metastatic HER2-negative drug-treatable population.
• Diagnosed drug-treated first-line unresectable/metastatic HER2-positive population.
• Diagnosed drug-treated first-line unresectable/metastatic HER2-negative population.
• Diagnosed non-drug-treated first-line unresectable/metastatic HER2-positive population.
• Diagnosed non-drug-treated first-line unresectable/metastatic HER2-negative population.
• … and many more (details available on request).

Note: Coverage may vary by country.